EA202092317A1 - Ингибитор белок-белковых взаимодействий фенилтриазольных соединений mll1-wdr5 - Google Patents
Ингибитор белок-белковых взаимодействий фенилтриазольных соединений mll1-wdr5Info
- Publication number
- EA202092317A1 EA202092317A1 EA202092317A EA202092317A EA202092317A1 EA 202092317 A1 EA202092317 A1 EA 202092317A1 EA 202092317 A EA202092317 A EA 202092317A EA 202092317 A EA202092317 A EA 202092317A EA 202092317 A1 EA202092317 A1 EA 202092317A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- protein
- wdr5
- mll1
- phenyltriazole
- inhibitor
- Prior art date
Links
- LUEYUHCBBXWTQT-UHFFFAOYSA-N 4-phenyl-2h-triazole Chemical class C1=NNN=C1C1=CC=CC=C1 LUEYUHCBBXWTQT-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000003993 interaction Effects 0.000 title 1
- 230000004850 protein–protein interaction Effects 0.000 abstract 2
- 101000771599 Homo sapiens WD repeat-containing protein 5 Proteins 0.000 abstract 1
- 102100029445 WD repeat-containing protein 5 Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Настоящее изобретение относится к области медицинской химии, в частности к классу ингибиторов белок-белкового взаимодействия фенилтриазол MLL1-WDR5 (I) и способу его получения, и фармакодинамические исследования доказывают, что соединение по настоящему изобретению характеризуется относительно сильной ингибиторной активностью белок-белкового взаимодействия MLL1-WDR5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810365880.0A CN108715585A (zh) | 2018-04-23 | 2018-04-23 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
| PCT/CN2018/123500 WO2019205687A1 (zh) | 2018-04-23 | 2018-12-25 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092317A1 true EA202092317A1 (ru) | 2021-07-23 |
Family
ID=63899366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092317A EA202092317A1 (ru) | 2018-04-23 | 2018-12-25 | Ингибитор белок-белковых взаимодействий фенилтриазольных соединений mll1-wdr5 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11479545B2 (ru) |
| EP (1) | EP3786157B1 (ru) |
| JP (1) | JP7274765B2 (ru) |
| KR (1) | KR20210019414A (ru) |
| CN (2) | CN108715585A (ru) |
| AU (1) | AU2018420231B2 (ru) |
| BR (1) | BR112020021569A2 (ru) |
| CA (1) | CA3097925A1 (ru) |
| CL (1) | CL2020002736A1 (ru) |
| CO (1) | CO2020014430A2 (ru) |
| EA (1) | EA202092317A1 (ru) |
| IL (1) | IL278255B2 (ru) |
| MX (1) | MX2020011205A (ru) |
| PH (1) | PH12020551756A1 (ru) |
| SG (1) | SG11202010492SA (ru) |
| WO (1) | WO2019205687A1 (ru) |
| ZA (1) | ZA202006581B (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019261273B2 (en) | 2018-04-23 | 2023-03-09 | Celgene Corporation | Substituted 4-aminoisoindoline-1,3-dione compounds and their use for treating lymphoma |
| CN108715585A (zh) | 2018-04-23 | 2018-10-30 | 中国药科大学 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
| CN109734674B (zh) * | 2019-02-26 | 2022-08-26 | 中国药科大学 | 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途 |
| US20230286948A1 (en) * | 2022-03-14 | 2023-09-14 | Huyabio International, Llc | Haloalkylpyridyl triazole mll1-wdr5 protein-protein interaction inhibitor |
| WO2023177593A1 (en) * | 2022-03-14 | 2023-09-21 | Huyabio International, Llc | Phenyl triazole mll1-wdr5 protein-protein interaction inhibitor |
| WO2024002379A1 (zh) * | 2022-07-01 | 2024-01-04 | 甘李药业股份有限公司 | 一种用作wdr5抑制剂的化合物或其可药用盐及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1692116B1 (en) * | 2003-12-03 | 2011-03-09 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,2,3-triazole amide derivatives as inhibitors of cytokine production |
| WO2011149827A1 (en) | 2010-05-24 | 2011-12-01 | Glaxosmithkline Llc | Compounds and methods |
| CN104844573A (zh) | 2015-04-17 | 2015-08-19 | 中国药科大学 | 嘧啶类btk抑制剂、其制备方法及医药用途 |
| CN105175284B (zh) * | 2015-07-21 | 2017-06-16 | 中国药科大学 | 酰胺类化合物、制备方法及其医药用途 |
| RU2018128334A (ru) | 2016-02-09 | 2020-03-10 | Инвентисбио Инк. | Ингибиторы индоламин-2,3-диоксигеназы (ido) |
| AU2017226005A1 (en) * | 2016-03-01 | 2018-09-06 | Propellon Therapeutics Inc. | Inhibitors of WDR5 protein-protein binding |
| US11319299B2 (en) | 2016-03-01 | 2022-05-03 | Propellon Therapeutics Inc. | Substituted carboxamides as inhibitors of WDR5 protein-protein binding |
| CN107382840B (zh) | 2016-05-16 | 2020-09-01 | 四川大学 | 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途 |
| WO2019127385A1 (en) | 2017-12-29 | 2019-07-04 | Shenzhen United Imaging Healthcare Co., Ltd. | Systems and methods for patient positioning |
| CN108715585A (zh) | 2018-04-23 | 2018-10-30 | 中国药科大学 | 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂 |
-
2018
- 2018-04-23 CN CN201810365880.0A patent/CN108715585A/zh active Pending
- 2018-12-25 EA EA202092317A patent/EA202092317A1/ru unknown
- 2018-12-25 BR BR112020021569-4A patent/BR112020021569A2/pt unknown
- 2018-12-25 CN CN201880092659.0A patent/CN112368268A/zh active Pending
- 2018-12-25 CA CA3097925A patent/CA3097925A1/en active Pending
- 2018-12-25 KR KR1020207033699A patent/KR20210019414A/ko active IP Right Grant
- 2018-12-25 IL IL278255A patent/IL278255B2/en unknown
- 2018-12-25 WO PCT/CN2018/123500 patent/WO2019205687A1/zh active Application Filing
- 2018-12-25 MX MX2020011205A patent/MX2020011205A/es unknown
- 2018-12-25 EP EP18916025.2A patent/EP3786157B1/en active Active
- 2018-12-25 SG SG11202010492SA patent/SG11202010492SA/en unknown
- 2018-12-25 AU AU2018420231A patent/AU2018420231B2/en active Active
- 2018-12-25 JP JP2020558628A patent/JP7274765B2/ja active Active
-
2020
- 2020-10-22 US US17/078,052 patent/US11479545B2/en active Active
- 2020-10-22 PH PH12020551756A patent/PH12020551756A1/en unknown
- 2020-10-22 ZA ZA2020/06581A patent/ZA202006581B/en unknown
- 2020-10-22 CL CL2020002736A patent/CL2020002736A1/es unknown
- 2020-11-20 CO CONC2020/0014430A patent/CO2020014430A2/es unknown
-
2022
- 2022-09-14 US US17/944,757 patent/US12054478B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN112368268A (zh) | 2021-02-12 |
| IL278255B1 (en) | 2023-05-01 |
| CN108715585A (zh) | 2018-10-30 |
| US20230098016A1 (en) | 2023-03-30 |
| EP3786157B1 (en) | 2024-08-07 |
| AU2018420231A1 (en) | 2020-12-10 |
| AU2018420231B2 (en) | 2024-08-22 |
| JP7274765B2 (ja) | 2023-05-17 |
| US11479545B2 (en) | 2022-10-25 |
| MX2020011205A (es) | 2021-02-09 |
| SG11202010492SA (en) | 2020-11-27 |
| US20210139466A1 (en) | 2021-05-13 |
| CA3097925A1 (en) | 2019-10-31 |
| EP3786157A4 (en) | 2022-01-05 |
| BR112020021569A2 (pt) | 2021-04-13 |
| WO2019205687A1 (zh) | 2019-10-31 |
| PH12020551756A1 (en) | 2021-08-16 |
| JP2021525226A (ja) | 2021-09-24 |
| ZA202006581B (en) | 2023-05-31 |
| EP3786157A1 (en) | 2021-03-03 |
| IL278255B2 (en) | 2023-09-01 |
| CL2020002736A1 (es) | 2021-05-28 |
| US12054478B2 (en) | 2024-08-06 |
| CO2020014430A2 (es) | 2021-05-20 |
| IL278255A (ru) | 2020-12-31 |
| KR20210019414A (ko) | 2021-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202092317A1 (ru) | Ингибитор белок-белковых взаимодействий фенилтриазольных соединений mll1-wdr5 | |
| EA201990851A1 (ru) | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 | |
| CL2018000374A1 (es) | Sales de un inhibidor de lsd1 | |
| EA202191890A1 (ru) | Ингибиторы pcsk9 и способы их применения | |
| AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
| EA201890573A1 (ru) | Новые замещенные 6-6-бициклическим ароматическим кольцом аналоги нуклеозидов для применения в качестве ингибиторов prmt5 | |
| EA201890338A1 (ru) | Оксадиазольные производные, пригодные в качестве ингибиторов hdac | |
| EA201891974A1 (ru) | Ингибиторы связывания белка wdr5 с белками | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201591382A1 (ru) | Ингибиторы гистондеметилаз | |
| EA201792535A1 (ru) | Гетероциклические амиды в качестве ингибиторов киназ | |
| EA201691401A1 (ru) | Индазольные соединения в качестве ингибиторов irak4 | |
| EA202092263A1 (ru) | Аминопиридиновые производные в качестве ингибиторов ctps1 | |
| EA201792259A1 (ru) | Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения | |
| EA201400735A1 (ru) | Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы | |
| EA202191892A1 (ru) | Ингибиторы pcsk9 и способы их применения | |
| EA201690598A1 (ru) | Аминогетероарил бензамиды в качестве ингибиторов киназы | |
| EA201792548A1 (ru) | 4-гидрокси-3-(гетероарил)пиридин-2-оновые агонисты apj для применения в лечении сердечно-сосудистых заболеваний | |
| EA201991884A3 (ru) | Ингибиторы g12c kras | |
| EA201791955A1 (ru) | ИНГИБИТОРЫ TGF-β | |
| EA201692265A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201592182A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| EA201992137A1 (ru) | ПИРИМИДОПИРИМИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ Wee-1 |